Efficacy and Safety of ABC008 in Inclusion Body Myositis

The ABC008 Study is a double blind, placebo controlled study investigating subcutaneous injections of ABC008 to treat inclusion body myositis.

The ABC008 trial is broken up into three parts. The first part is 84 weeks in length and subjects are randomized into 2 (low dose):2 (high dose):1(placebo) treatment groups, meaning a 1 in 5 chance of receiving placebo. Following results from the first part of the trial, the second part (part B) will randomize subjects into a 1 (low dose): 1 (high dose): 1 (placebo) treatment groups. Meaning a 1 in 3 chance of receiving placebo. The third part of the trial is open label, where are participants receive the study drug.

This is an industry sponsored trial and Yale is one of approximately 60 sites participating across the United States, Canada, Europe, and Australia.